Advertisement

Topics

US FDA grants breakthrough therapy designation for AstraZeneca’s MCL treatment

19:00 EDT 2 Aug 2017 | Pharmaceutical Technology

AstraZeneca’s acalabrutinib has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

Original Article: US FDA grants breakthrough therapy designation for AstraZeneca’s MCL treatment

NEXT ARTICLE

More From BioPortfolio on "US FDA grants breakthrough therapy designation for AstraZeneca’s MCL treatment"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...